Hamid Obeid, MD
Otolaryngology · Rome, NYNPI 1548251663
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,426 of the $15,361 with a category attached, or 61.4%. 25 manufacturers reported payments, led by Medtronic at 29.5% of the total. Reporting peaked in 2022 at $5,580 and has fallen 66.6% since, to $1,865 in 2025. Among otolaryngology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 374 payments — averaging $41.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$5K
- Aerin Medical Inc.$2K
- Integra Lifesciences Corporation$1K
- AstraZeneca$1K
- GSK$1K
- Intersect ENT, Inc.$900
- plus $4K from 19 others
What the payments were for
- Travel & lodging$5,93539%
- Food & beverage$9,42661%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 98 | $4,539 |
| Aerin Medical Inc. | 27 | $2,224 |
| Integra Lifesciences Corporation | 11 | $1,360 |
| AstraZeneca | 46 | $1,225 |
| GSK | 41 | $1,044 |
| Intersect ENT, Inc. | 19 | $900 |
| Acclarent, Inc | 25 | $891 |
| Medical Device Business Services, Inc. | 7 | $826 |
| Sanofi | 22 | $610 |
| Optinose US, Inc. | 26 | $496 |
| Regeneron Healthcare Solutions, Inc. | 19 | $423 |
| Smith+Nephew | 6 | $171 |
| Biohaven Pharmaceuticals, Inc. | 2 | $133 |
| Alk-abello, Inc | 8 | $114 |
| Biosense Webster, Inc. | 1 | $75 |
| Stryker | 3 | $66 |
| Arbor Pharmaceuticals, Inc. | 2 | $46 |
| AbbVie | 2 | $46 |
| Olympus America Inc. | 1 | $34 |
| Neurent Medical Limited | 1 | $32 |
| Acelrx Pharmaceuticals, Inc. | 2 | $30 |
| MDD US Operations, LLC | 2 | $30 |
| Novartis | 1 | $23 |
| Ambu Inc. | 1 | $18 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTEGRA$3,369
- PROPEL$3,185
- VIVAER STYLUS$1,615
- INTEGRA DERMAL REGENERATION TEMPLATE$1,123
- PRIMATRIX$1,123
- SINUVA$723
- BREZTRI$365
- RHINAER STYLUS$288
- Acclarent Aera$136
- TRELEGY ELLIPTA$125
- NURTEC ODT$125
- DUPIXENT$125
- Xhance$121
How this compares
$15,361 in reported general payments places this provider in the 90th percentile of 701 otolaryngology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 13 | $44,641 |
| Dexamethasone Sodium Phosphate | 312 | $14,933 |
| XhanceFluticasone Propionate | 18 | $12,724 |
| Fluticasone Propionate | 300 | $4,269 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 25 | $3,275 |
| Azelastine Hcl | 121 | $2,653 |
| Mometasone Furoate | 37 | $1,711 |
| Cevimeline Hcl | 13 | $1,100 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 45 | $408 |
| Ondansetron OdtOndansetron | 45 | $382 |
| Omeprazole | 31 | $370 |
| Ipratropium Bromide | 17 | $326 |
| Dexamethasone | 48 | $311 |
| Sucralfate | 13 | $215 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 32 | $197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $496 | $12,72418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 701 otolaryngology providers in New York.
Other otolaryngology in Rome
- Robert KellmanSyracuse$2.5M
- Roheen RaithathaNew York$830K
- Nora PerkinsAlbany$300K
- Moshe EphratNew Hyde Park$250K
- Gavin SetzenAlbany$243K
- Habibullah JamalRye Brook$179K
- Albert JenFlushing$171K
- Dennis KrausNew York$159K
- Nitin BhatiaWhite Plains$120K
- Sveta KarelskyRochester$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.